Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases, with a particular emphasis on autoimmune kidney disorders such as immunoglobulin A nephropathy (IgAN). The VERA news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow key clinical, regulatory, and corporate developments affecting the stock.
News about Vera Therapeutics frequently centers on its lead product candidate, atacicept, an investigational fusion protein targeting BAFF and APRIL. Recent announcements include submission and U.S. FDA Priority Review of a Biologics License Application for atacicept in adults with IgAN, supported by data from the ORIGIN Phase 2b and ORIGIN 3 Phase 3 trials. The company has highlighted statistically significant and clinically meaningful reductions in proteinuria and a safety profile described as comparable to placebo, as well as presentations at major scientific meetings and publication of trial results in The New England Journal of Medicine.
Investors and followers of VERA stock can also expect news on pipeline expansion and broader immunology programs. Vera Therapeutics reports ongoing evaluation of atacicept in expanded IgAN populations and other autoimmune kidney diseases, along with development of VT-109, a next-generation BAFF/APRIL-targeting fusion protein licensed from Stanford University, and MAU868, a monoclonal antibody designed to neutralize BK virus infection in kidney transplant recipients.
In addition, the news flow includes capital markets and corporate updates, such as underwritten public offerings of Class A common stock, at-the-market sales agreements, inducement equity grants under the company’s 2024 Inducement Plan, and changes in board composition or executive roles disclosed via Form 8-K. Vera Therapeutics also announces participation in healthcare and investor conferences, where its management team presents clinical data and corporate strategy.
By reviewing the VERA news page regularly, readers can track how clinical milestones, regulatory decisions, financing activities, and governance changes may relate to Vera Therapeutics’ development programs and its position as a late clinical-stage biotech issuer.
Vera Therapeutics, a late clinical-stage biotechnology company, has announced the pricing of its public offering of 7,142,858 shares of Class A common stock at $42.00 per share. The offering is expected to generate approximately $300.0 million in gross proceeds before deducting underwriting costs and expenses. The company has granted underwriters a 30-day option to purchase up to an additional 1,071,428 shares. The offering is expected to close on October 31, 2024, with J.P. Morgan, Goldman Sachs, Evercore ISI, and Cantor serving as joint book-running managers.
Vera Therapeutics (VERA), a late clinical-stage biotechnology company, has announced plans for a $300 million public offering of Class A common stock. The company will grant underwriters a 30-day option to purchase up to an additional 15% of shares. J.P. Morgan, Goldman Sachs & Co. , Evercore ISI and Cantor are acting as joint book-running managers. The offering will be made through an automatic shelf registration statement on Form S-3 filed with the SEC on October 28, 2024.
Vera Therapeutics (NASDAQ: VERA) announced 96-week data from its ORIGIN Phase 2b trial of atacicept in IgA nephropathy (IgAN), showing stabilized kidney function. The results, presented at ASN Kidney Week 2024, demonstrated -66% reduction in Gd-IgA1, 75% resolution of hematuria, -52% reduction in proteinuria, and a mean annualized eGFR slope of -0.6 mL/min/1.73m2/year. The trial maintained a 90% completion rate with a favorable safety profile. The company expects topline results from Phase 3 ORIGIN 3 trial in Q2 2025, with planned BLA submission later that year.
Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted to seven new employees on October 2, 2024. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), include:
1. Non-qualified stock options to purchase 125,000 shares of Class A common stock
2. Restricted stock units (RSUs) for 62,500 shares of Class A common stock
The stock options have an exercise price of $41.75 per share, equal to Vera's closing price on October 2, 2024. They will vest over four years, with 25% vesting on the first anniversary and the remainder monthly over 36 months. The RSUs will vest over four years, with 25% vesting annually starting November 20, 2024. Both awards are subject to continued employment and the terms of the Inducement Plan and applicable award agreements.
Vera Therapeutics (Nasdaq: VERA) announced that long-term results from the ORIGIN Phase 2b clinical trial of atacicept for IgAN treatment will be presented at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, from October 23 to 27. The presentation will be delivered by Dr. Jonathan Barratt on October 26. Additionally, two informational posters describing the ORIGIN Phase 3 and ORIGIN Extend trials will be presented by Dr. Richard Lafayette on October 25.
Vera will also host an in-person and virtual R&D Day in New York on October 2, 2024, featuring experts Dr. Jonathan Barratt, Dr. Richard Lafayette, and Dr. Brad Rovin, who will discuss Vera's expanded atacicept R&D activities.
Vera Therapeutics (Nasdaq: VERA) announced an expansion of its development pipeline for atacicept, its lead asset. The company plans to extend the drug's application beyond IgA nephropathy (IgAN) to other autoimmune kidney diseases. Key points include:
1. ORIGIN Extend: A study providing extended access to atacicept for ORIGIN participants, starting Q4 2024.
2. PIONEER Study: Planned for 2025, evaluating atacicept in expanded IgAN populations and other autoimmune glomerular diseases.
3. The combined peak prevalence of target diseases in the US is estimated at ~230,000.
4. 96-week data from the Phase 2b ORIGIN study will be presented at the American Society of Nephrology Kidney Week 2024.
Vera Therapeutics (Nasdaq: VERA) has announced an in-person and virtual R&D Day on October 2, 2024, in New York. The event will focus on potential indication expansion for atacicept, their lead drug candidate. Notable experts, including Dr. Jonathan Barratt, Dr. Richard Lafayette, and Dr. Brad Rovin, will join Vera's management team to discuss expanded atacicept R&D activities.
This event precedes the anticipated 96-week data from the Phase 2b ORIGIN study of atacicept in immunoglobulin A nephropathy (IgAN), scheduled for presentation at a medical congress in Q4 2024. Notably, atacicept has received FDA Breakthrough Therapy Designation for IgAN treatment, indicating its potential for substantial improvement over existing therapies based on Phase 2b ORIGIN trial data.
Vera Therapeutics (Nasdaq: VERA) has completed enrollment for the primary endpoint in its pivotal Phase 3 ORIGIN 3 trial of atacicept in IgA Nephropathy (IgAN) patients. The trial enrolled 200 participants, with topline results expected in Q2 2025. The company plans to present 96-week data from the Phase 2b ORIGIN trial in Q4 2024. Atacicept has shown promising results in stabilizing kidney function and reducing hematuria, potentially transforming IgAN treatment. The FDA granted atacicept Breakthrough Therapy Designation earlier this year. Vera believes atacicept could be among the first B cell modulators approved for IgAN, offering a new foundation for treating this organ-threatening disease.
Vera Therapeutics (Nasdaq: VERA) announced inducement awards for two new employees on September 5, 2024. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), include:
1. A non-qualified stock option to purchase 21,750 shares of Class A common stock
2. Restricted stock units (RSUs) for 9,875 shares of Class A common stock
The stock option has an exercise price of $38.16 per share, based on Vera's closing price on September 5, 2024. It will vest over four years, with 25% vesting on the first anniversary and the remainder monthly over 36 months. The RSUs will vest over four years, with 25% vesting annually starting November 20, 2024. Both awards are subject to continued employment and the terms of the Inducement Plan and award agreements.
Vera Therapeutics (Nasdaq: VERA), a late clinical-stage biotech company, announced its participation in two investor conferences in September 2024. The company, which focuses on developing treatments for serious immunological diseases, will attend:
1. Wells Fargo Healthcare Conference on September 5 in Boston, MA, participating in one-on-one meetings.
2. Cantor Global Healthcare Conference on September 18 in New York, NY, featuring a fireside chat at 9:10am EDT and one-on-one meetings.
A webcast of the Cantor conference presentation will be available, with a 90-day replay accessible on Vera Therapeutics' website in the 'Investor Calendar' section.